About Mallinckrodt Warfarin
Since the late 1800’s, Mallinckrodt has been supplying pharmaceutical products to pharmacists, making us a trusted expert in the industry. Mallinckrodt’s Warfarin Sodium Tablets, USP, are another example of the quality generic products we can provide.
Mallinckrodt’s Warfarin Sodium Tablets, USP, are AB rated to Coumadin®*. This means that, like apples to apples, our generic has the same clinical effect as the brand Coumadin®*.
Mallinckrodt recognizes the importance in understanding anticoagulation therapy — both for the patient and the healthcare provider. Further information can be found on this site, assisting you with any questions you may have.
Mallinckrodt’s Warfarin Sodium Tablets, USP are available in nine strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg, and 10mg.
Important Safety Information
Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism.
WARNING: BLEEDING RISK
Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur during the starting period and with a higher dose (resulting in a higher INR). Risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age ≥65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS in full prescribing information), and long duration of warfarin therapy. Regular monitoring of INR should be performed on all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shorter duration of therapy. Patients should be instructed about prevention measures to minimize risk of bleeding and to report immediately to physicians signs and symptoms of bleeding (see PRECAUTIONS in full prescribing information).
Anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater that the potential clinical benefits of anticoagulation, such as: in women who are or may become pregnant, because Warfarin may cause fatal hemorrhage to the fetus and reports of birth malformations; recent or contemplated surgery of the central nervous system, eye or traumatic surgery with large open surfaces; bleeding tendencies associated with active ulceration; threatened abortion, inadequate laboratory facilities; unsupervised patients; spinal puncture.
*Coumadin
is a registered trademark of Bristol-Myers Squibb Company.
All trademarks are owned by Mallinckrodt Inc. unless otherwise noted.
